Levodopa shows promise against macular degeneration

Levodopa shows promise against macular degeneration

(HealthDay)— Levodopa (L-dopa) might hold potential for preventing or treating macular degeneration, according to a study published online Oct. 30 in The American Journal of Medicine.

Researchers analyzed of 37,000 patients from a Wisconsin clinic. The researchers looked for signs whether or not those who took levodopa had lower rates of . They also examined a medical database of 87 million people.

The researchers found that diagnosis of age-related macular degeneration occurred, in general, around age 71. But among those who took , it occurred much later, at around age 79.

According to lead author Brian S. McKay, Ph.D., an associate professor of ophthalmology and vision science at the University of Arizona in Tucson, the drug may affect development of age-related macular degeneration by protecting photoreceptors.

Explore further

Leading cause of blindness could be prevented or delayed

More information: Abstract
Full Text
Journal information: American Journal of Medicine

Copyright © 2015 HealthDay. All rights reserved.

Citation: Levodopa shows promise against macular degeneration (2015, November 13) retrieved 29 June 2022 from https://medicalxpress.com/news/2015-11-levodopa-macular-degeneration.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors